Please wait a minute...
Reviews in Cardiovascular Medicine  2015, Vol. 16 Issue (2): 114-124     DOI: 10.3909/ricm0755
Review Previous articles | Next articles
Renal Denervation: Past, Present, and Future
Bashar Hannawi, Homam Ibrahim, Colin M. Barker
Houston Methodist Hospital, Houston, TX
Download:  PDF(748KB)  ( 121 )
Export:  BibTeX | EndNote (RIS)      
Hypertension remains a leading cause of cardiovascular morbidity and mortality worldwide. It is estimated that 12.8% of hypertensive adults have resistant hypertension. The sympathetic nervous system is a well-known contributor to the pathophysiology of resistant hypertension. Renal denervation has emerged as an effective procedure to treat resistant hypertension by blocking the sympathetic nervous system. The medical device industry has developed various catheters in an effort to achieve better denervation in the absence of available testing to document adequate denervation. By adding a sham control group to the study design, researchers found that the results of the Renal Denervation in Patients With Uncontrolled Hypertension study (SYMPLICITY HTN-3) showed that renal denervation was not superior to placebo in decreasing systolic blood pressure. Although SYMPLICITY HTN-3 successfully addressed many issues that might have biased the previously published data, incomplete denervation caused by limited operator experience, catheter design, and the radiofrequency ablation technology may have accounted for the discrepancy of the results. This, along with differences in the study design and population, should direct future renal denervation studies. This article reviews the available literature and proposes future directions for renal denervation studies. It also provides a detailed comparison of the available catheters and their respective clinical data.
Key words:  Renal denervation      Resistant hypertension      Interventional cardiology     
Published:  30 June 2015     

Cite this article: 

Bashar Hannawi, Homam Ibrahim, Colin M. Barker. Renal Denervation: Past, Present, and Future. Reviews in Cardiovascular Medicine, 2015, 16(2): 114-124.

URL:     OR

[1] Davide Bolignano, Giuseppe Coppolino. Renal nerve ablation for resistant hypertension: facts, fictions and future directions[J]. Reviews in Cardiovascular Medicine, 2019, 20(1): 9-18.
[2] Davide Bolignano, Giuseppe Coppolino. Baroreflex stimulation for treating resistant hypertension: ready for the prime-time?[J]. Reviews in Cardiovascular Medicine, 2018, 19(3): 89-95.
[3] Sabas I. Gomez, Pablo Urbandt, Nirat Beohar, Orlando Santana. Renal Denervation: Current Status and Future Applications[J]. Reviews in Cardiovascular Medicine, 2014, 15(4): 351-357.
[4] Timothy R. Larsen, Wadie David, Susan Steigerwalt, Shukri David. Primary Hyperaldosteronism Decoded: A Case of Curable Resistant Hypertension[J]. Reviews in Cardiovascular Medicine, 2012, 13(4): 203-208.
[5] David R. Holmes. Incidence of Late Stent Thrombosis With Bare-Metal, Sirolimus, and Paclitaxel Stents[J]. Reviews in Cardiovascular Medicine, 2007, 8(S1): 11-18.
No Suggested Reading articles found!